News and analysis on disease research and diagnostics.
The second EUA for a test that targets the ORF1a and N genes is for an automated version of a manual test that had been granted EUA in August.
Revenues have begun to recover in Q3, driven by a ramp in SARS-CoV-2 testing, and the firm now expects full-year 2020 revenues to exceed its prior guidance.
The supplement adds a collection vial to the BD Onclarity test and includes performance data for the BD Viper LT and the BD COR Systems.
The effort is part of a pilot program exploring what role drones could play in responding to the pandemic and healthcare delivery more generally.
The investment firm said that Grail's revenue trajectory is uncertain, and given the firm's operating loss, it will significantly dilute Illumina's earnings.
